SUPT16H and cancer: CBL0137 is a novel nongenotoxic anticancer drug belonging to a family of small molecules called curaxins [6], which exhibits antitumor activity by targeting FACT (facilitates chromatin transcription), a histone chaperone that is highly expressed and associated with increased aggressiveness, stemness, and poor prognosis in a variety of cancer types [6–18].